NASDAQ:NDRA ENDRA Life Sciences Q4 2024 Earnings Report $6.44 -0.68 (-9.55%) Closing price 04:00 PM EasternExtended Trading$6.37 -0.07 (-1.09%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast ENDRA Life Sciences EPS ResultsActual EPS-$9.40Consensus EPS -$4.10Beat/MissMissed by -$5.30One Year Ago EPSN/AENDRA Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AENDRA Life Sciences Announcement DetailsQuarterQ4 2024Date3/31/2025TimeBefore Market OpensConference Call DateMonday, March 31, 2025Conference Call Time9:00AM ETUpcoming EarningsENDRA Life Sciences' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) ENDRA Life Sciences Earnings HeadlinesENDRA Life Sciences Inc News (NDRA) - Investing.comJuly 3, 2025 | investing.comENDRA Life Sciences Inc. (NDRA) - Yahoo FinanceJune 25, 2025 | finance.yahoo.com[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.July 21 at 2:00 AM | Golden Portfolio (Ad)ENDRA’s Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold StandardJune 16, 2025 | finance.yahoo.comENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | businesswire.comENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business UpdateMarch 31, 2025 | finance.yahoo.comSee More ENDRA Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ENDRA Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ENDRA Life Sciences and other key companies, straight to your email. Email Address About ENDRA Life SciencesENDRA Life Sciences (NASDAQ:NDRA) (NASDAQ: NDRA) is a medical technology company focused on developing and commercializing advanced imaging solutions for clinical and preclinical applications. The company’s proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS) platform uses patented nanoemulsion-based contrast agents to generate high-resolution thermal maps of tissue. By combining ultrasound with thermoacoustic technology, ENDRA’s systems aim to provide clinicians with quantitative insights into tissue composition, addressing unmet needs in monitoring liver health, cancer therapy response and other disease states. Founded in 2009 and headquartered in Ann Arbor, Michigan, ENDRA has evolved from a research-driven start-up into a publicly traded entity following a Nasdaq listing in late 2014. Since its inception, the firm has collaborated with leading academic institutions and secured regulatory designations to support its clinical development programs. The company’s Strata™ platform is designed for noninvasive, point-of-care imaging of liver steatosis, while additional preclinical systems target drug development workflows by enabling real-time assessment of tissue changes in oncology and cardiovascular research models. ENDRA serves a range of geographies, with its principal markets in the United States and ongoing initiatives to expand into Europe and Asia through partnerships and clinical studies. The company’s leadership team combines experience in medical device innovation, regulatory affairs and commercialization. Under the direction of CEO Samer Nassif and Chief Medical Officer Sainil Harle, ENDRA continues to advance its TAEUS technology through pivotal trials, seeking to address growing healthcare challenges related to liver disease prevalence and the need for more effective imaging modalities.Written by Jeffrey Neal JohnsonView ENDRA Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom Upcoming Earnings Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025)CocaCola (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
